An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy
NCT01602120
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
159
Enrollment
INDUSTRY
Sponsor class
Stopped
The study was terminated early by the Sponsor due to lack of efficacy.
Conditions
Geographic Atrophy
Interventions
DRUG:
Lampalizumab
Sponsor
Genentech, Inc.